Effects of pravastatin treatment on lipoprotein levels and composition in patients with type 2 diabetes mellitus and hypercholesterolemia
| Autor: | Riccardo Trifirò, Renzo Navalesi, M. G. Giovannitti, Roberto Anichini, Anna Ceraudo, Adelaide Dolci, Roberto Miccoli |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
pravastatin treatment medicine.medical_treatment Type 2 diabetes Diabetes mellitus Internal medicine polycyclic compounds lipoprotein levels type 2 diabetes hypercolesterolemia Medicine Pharmacology (medical) Pharmacology Chemotherapy medicine.diagnostic_test business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus medicine.disease Hydroxymethylglutaryl-CoA reductase Endocrinology lipids (amino acids peptides and proteins) business Lipid profile Pravastatin medicine.drug Lipoprotein |
| Popis: | Objective To assess the effects of pravastatin on lipoprotein levels and composition in patients with type 2 diabetes mellitus and hypercholesterolemia. The role of pravastatin in glucose control also was assessed. Background Several factors, including abnormalities of lipoprotein composition, may contribute to the increased risk of coronary heart disease in diabetes mellitus. Methods Patients with type 2 diabetes mellitus of at least 3 years' duration entered the study at the 4-week run-in period, during which they received a standard diet. For the remaining 18 weeks of the study, they received pravastatin 20 mg/d. Results In 51 patients, pravastatin decreased total cholesterol concentrations (289 ± 40 to 227 ± 37) ( P P P P Conclusions In patients with type 2 diabetes mellitus and hypercholesterolemia, pravastatin improved the lipid profile and the atherogenic potential associated with abnormal lipoprotein composition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|